GtoPdb Ligand ID: 7335

Synonyms: BMS-936558 | MDX-1106 | ONO-4538 | Opdivo®
nivolumab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Nivolumab is an IgG4 kappa immunoglobulin that is selective for PD-1, an immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells [12]. This monoclonal is produced in Chinese hamster ovary cells by recombinant DNA technology. Nivolumab is an immuno-oncology drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Sequence analysis of the light and heavy chain variable region peptides of nivolumab shows exact matches with claimed peptide sequences of monoclonal 5C4 contained in patent WO2006121168 [10].
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2014), EMA (2015))
WHO Essential Medicine WHO Model List of Essential Medicines (21st List, 2019). Access PDF version.
International Nonproprietary Names
INN number INN
9623 nivolumab
BMS-936558 | MDX-1106 | ONO-4538 | Opdivo®
Database Links
Specialist databases
IMGT/mAb-DB 424
Other databases
GtoPdb PubChem SID 178103907
PubChem SID 178103907
Search PubMed clinical trials nivolumab
Search PubMed titles nivolumab
Search PubMed titles/abstracts nivolumab
Wikipedia nivolumab